Dallas, TX January 22, 2010
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today announced that it has entered into definitive agreements with accredited investors to sell in a registered direct offering an aggregate of 2.10 million shares of its common stock at a price of$3.00 per share for aggregate gross proceeds of $6.3 million. Additionally, at the closing, Access will issue to the investors warrants to purchase, in the aggregate, approx. 1.05 million shares of common stock at a price of $3.00 per share, which warrant are exercisable immediately for a term of 5 years from the closing date. The closing of the offering is expected to take place subject to the satisfaction of customary closing conditions. Read more »
DALLAS, TX, January 19, 2010
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body’s natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a “Trojan horse” mechanism. Access has focused its Cobalamin product development program on the oral delivery of insulin and human growth hormone, two peptides which currently can only be given by injection. A new Cobalamin-coated insulin-containing nanoparticle formulation delivered orally provided a pharmacological response (lowering of blood glucose levels in an animal model of diabetes) greater than 80% of that achieved by insulin delivered subcutaneously. This represents a substantial oral bioavailability, indicating that this formulation has potential for clinical development and ultimate commercialization. Adaptation of this technology has provided a Cobalamin human growth hormone formulation that has demonstrated good efficacy, represented by more than 25% improvement in weight gain, when given orally in an established animal model. Access continues to move both products towards clinical development, and plans to submit an additional patent application to protect the improvements to the technology. Read more »
Update on worldwide development on ProLindac
DALLAS, TX, January 7 2009
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens. The additional cohort of 8 patients received the ProLindac batch made by an improved scalable process, which will be used on a larger scale for future clinical and commercial supplies. None of the 8 patients experienced any acute significant adverse events, while treatment had the same beneficial pharmacodynamic effect seen in the first 26 patients treated with the former ProLindac production batch; clinically relevant sustained biomarker decrease (responses by Rustin’s criteria) and disease stabilization were seen in several patients. The overall results of our Phase I/II exploratory single agent ProLindac study have helped define multiple safe dosing regimens, while the level of patient cohort accrued in the study antitumor activity was as expected in this very heavily pretreated patient cohort. Read more »
Dallas, TX, January 6, 2010
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced President and CEO Jeffrey B. Davis will provide an update on Access’ product and clinical development plans for 2010 during a presentation at the OneMedPlace’s Forum 2010, Emerging Company Finance Conference, on Wednesday, January 13, 2010, at 3:00 p.m. Pacific time (6:00 p.m. Eastern time). The conference is being held at the Sir Francis Drake Hotel in San Francisco.
Read more »
Tweet
Digg!
Del.icio.us
Follow Us
Accesspharma: RT @